The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
High-Density Lipoprotein Function, Dysfunction, and Reverse Cholesterol Transport
Open accessAbstract
Although high high-density lipoprotein (HDL)-cholesterol levels are associated with decreased cardiovascular risk in epidemiological studies, recent genetic and pharmacological findings have raised doubts about the beneficial effects of HDL. Raising HDL levels in animal models by infusion or overexpression of apolipoprotein A-I has shown clear vascular improvements, such as delayed atherosclerotic lesion progression and accelerated lesion regression, along with increased reverse cholesterol transport. Inflammation and other factors, such as myeloperoxidase-mediated oxidation, can impair HDL production and HDL function, with regard to its reverse cholesterol transport, antioxidant, and anti-inflammatory activities. Thus, tests of HDL function, which have not yet been developed as routine diagnostic assays, may prove useful and be a better predictor of cardiovascular risk than HDL-cholesterol levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
The plasma lecithin:cholesterol acyltransferase reaction
Glomset, J. A. (1968) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43114-1 · Cited by 2,405
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943 · cited 1×
“Although both treatments led to small increases in HDL-C, only the Pioglitazone-treated group had a small (11%) but significant increase in cholesterol acceptor activity.(32)”
BackgroundNissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707
Incidence of Coronary Heart Disease and Lipoprotein Cholesterol Levels: The Framingham Study
Castelli, W. P. (1986) · JAMA · doi:10.1001/jama.1986.03380200073024 · Cited by 1,611
The Framingham Study: The Epidemiology of Atherosclerotic Disease
Dawber, T. R. (1980) · Harvard University Press eBooks · doi:10.4159/harvard.9780674492097 · Cited by 1,454
Bouhlel, M. A., Derudas, B., Rigamonti, E., Dièvart, R., Brozek, J., Haulon, S., Zawadzki, C., Jude, B., Torpier, G., Marx, N., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.06.010 · Cited by 1,325
MiR-33 Contributes to the Regulation of Cholesterol Homeostasis
Rayner, K. J., Suárez, Y., Dávalos, A., Parathath, S., Fitzgerald, M. L., Tamehiro, N., Fisher, E. A., Moore, K. J., & Fernández-Hernando, C. (2010) · Science · doi:10.1126/science.1189862 · Cited by 1,260
Self-citation
Cited by
Pathophysiology of Atherosclerosis
Jebari-Benslaiman, S., Galicia-García, U., Larrea-Sebal, A., Olaetxea, J. R., Alloza, I., Vandenbroeck, K., Benito-Vicente, A., & Martín, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063346 · Cited by 1,010
Dysfunctional HDL and atherosclerotic cardiovascular disease
Rosenson, R. S., Brewer, H. B., Ansell, B. J., Barter, P., Chapman, M. J., Heinecke, J. W., Kontush, A., Tall, A. R., & Webb, N. R. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.124 · Cited by 822
Ouimet, M., Barrett, T. J., & Fisher, E. A. (2019) · Circulation Research · doi:10.1161/circresaha.119.312617 · Cited by 761
Self-citationThe Gut Microbial Endocrine Organ: Bacterially Derived Signals Driving Cardiometabolic Diseases
Brown, J. M., & Hazen, S. L. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-060513-093205 · Cited by 438
Self-citationAn abundant dysfunctional apolipoprotein A1 in human atheroma
Huang, Y., DiDonato, J. A., Levison, B. S., Schmitt, D., Li, L., Wu, Y., Buffa, J., Kim, T., Gerstenecker, G. S., Gu, X., et al. (2014) · Nature Medicine · doi:10.1038/nm.3459 · Cited by 364
Self-citationMackness, M., & Mackness, B. (2015) · Gene · doi:10.1016/j.gene.2015.04.088 · Cited by 310
Lüscher, T. F., Landmesser, U., von Eckardstein, A., & Fogelman, A. M. (2014) · Circulation Research · doi:10.1161/circresaha.114.300935 · Cited by 291
How Do Elevated Triglycerides and Low HDL-Cholesterol Affect Inflammation and Atherothrombosis?
Welty, F. K. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0400-4 · Cited by 221
From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk
Shapiro, M. D., & Fazio, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306471 · Cited by 217
Anti-inflammatory effects of diet and caloric restriction in metabolic syndrome
Montefusco, L., D’Addio, F., Loretelli, C., Ben Nasr, M., Garziano, M., Rossi, A., Pastore, I., Plebani, L., Lunati, M. E., Bolla, A. M., et al. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01547-y · Cited by 65
Treatment of dyslipidemia in diabetes: recent advances and remaining questions
Chait, A., & Goldberg, I. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0942-8 · Cited by 40
HDL Hypothesis: Where Do We Stand Now?
Tariq, S. M., Sidhu, M. S., Toth, P. P., & Boden, W. E. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0398-0 · Cited by 31
Sofra, X., & Badami, S. (2020) · Health · doi:10.4236/health.2020.128076 · Cited by 17
A model to predict unstable carotid plaques in population with high risk of stroke
Yin, J., Yu, C., Liu, H., Du, M., Sun, F., Yu, C., Wei, L., Wang, C., & Wang, X. (2020) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01450-z · Cited by 10
Metadata
- Authors
- Fisher, E. A., Feig, J. E., Hewing, B., Hazen, S. L., & Smith, J. D.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2012-12
- Volume
- 32
- Issue
- 12
- Pages
- 2813-2820
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2133990668
- Cited by
- 393
- References
- 75
- FWCI
- 32.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.